Partner Content Partner Content Attendee List Released for SMi’s 9th Annual RNA Therapeutics RNA Therapeutics
News BI drug named Promising Innovative Medicine in mesothelioma Boehringer Ingelheim is the latest company to gain a Promising Innovative Medicine (PIM) status in the UK for one of its drugs.
Views & Analysis How can the UK improve in clinical research? A biotech persp... The UK is a great place for early-stage research – but NHS red tape and market access remain major barriers.
Views & Analysis Pharma and med device sectors being forced into Hard Brexit ... Brexit is already forcing parts of the medical device sector to leave the UK – will pharma have to follow?
News Orchard’s gene therapy gains UK ‘promising innovative medici... A UK biotech start-up has gained a sought after ‘promising innovative medicine’ (PIM) designation for its ultra-rare disease gene therapy.
Market Access Policy in focus: Trump’s Most Favoured Nations drug pricing ... Alice Valder Curran, a partner at Hogan Lovells, provides an update on what's happening right now with Most Favoured Nations drug pricing.
Sales & Marketing FH25: Individual centric investing with Steve Seuntjens In a new FH25 podcast episode, Deep Dive editor Eloise McLennan speaks with Steve Seuntjens, Partner at PHS Capital.
